Navigation Links
Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
Date:2/3/2009

peutic candidates, please visit www.cardiumthx.com or view its most recent Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that human clinical trials can be conducted and completed in an efficient and successful manner, that FDA, CE Mark or other regulatory clearances or UL or other certifications, or partnering or other distribution agreements or other commercialization efforts will be successful or will effectively accelerate the business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of comple
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... market the TriPollar Technology- the most advanced 3rd generation Radio Frequency ... have been clinically proven the world over to be safe and ... non-invasive and patients enjoy visible results from the very 1st treatment. ... treatments. , ... Tel Aviv, Israel (PRWEB) ...
(Date:12/6/2009)... Conn., Dec. 6 Boehringer Ingelheim today ... etexilate (150 mg BID), a direct thrombin inhibitor ... acute VTE. Results of the trial were ... Annual Meeting and simultaneously published online in the ... ,, Dabigatran etexilate met the primary outcome of ...
(Date:12/4/2009)... Products (ACAMP) hosts, health & ... Today ACAMP hosted a health & medical seminar, ... can play a powerful role in the creation ... and improve the quality, cost and outcomes of ...
(Date:12/3/2009)... of Houston, LLC announced today that it has ... option, vertical sleeve gastrectomy , along with the ... first sleeve gastrectomy procedure at the facility was performed ... on October 20, 2009. The patient is reported as ...
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
... TeleHealth Services , the ... education, healthcare televisions and communications solutions, today announced a ... The facility opened Park Tower, a new wing of ... TeleHealth Services as its healthcare television provider. "When ...
... MINNEAPOLIS, April 28 Techne Corporation (Nasdaq: TECH ... pay a dividend of $0.25 per share for the quarter ... payable May 22, 2009 to all common shareholders of record ... considered by the Board of Directors on a quarterly basis.Techne,s ...
... healthy volunteer study of IMX942 will provide human safety ... - Inimex Pharmaceuticals is pleased to announce that its ... human subjects for the first time on April 27, ... 1 safety study of IMX942 being performed for Inimex ...
Other Biology Technology:TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 2TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower 3Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program 2Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator 2
(Date:12/3/2009)... Preliminary Press Conference Topics, Last Call! Press Field ... PIOs: Sending Press Releases to Fall meeting, NCSWA ... Media registration information , News Media Registration Form ... , For important information regarding visas for ...
(Date:12/3/2009)... N.M. Most scientists believe that staph infections are caused ... toxins. The signaling process is called quorum sensing because many ... the Jeff Brinker research group has determined that the very ... harmless to a virulent form, occurs in a single cell ...
(Date:12/3/2009)... reef fish can undergo a personality change in warmer water, ... may make some species more aggressive. , Experiments with two ... shown for the first time that some reef fish are ... differences are even more marked as water temperatures rise. , ...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Fish with attitude: Some like it hot 2Launch of First Year Round Annual Scientific Medical Meeting Announced at Health 2 0 59299 1Launch of First Year Round Annual Scientific Medical Meeting Announced at Health 2 0 59299 2California Walnuts Popular Smart Menus Program Getting Smarter 59297 1California Walnuts Popular Smart Menus Program Getting Smarter 59297 2California Walnuts Popular Smart Menus Program Getting Smarter 59297 3Regulatory Leader in OASIS Documentation Introduces OASIS C Products 5400 1Regulatory Leader in OASIS Documentation Introduces OASIS C Products 5400 2
... international research team believes that changes in behaviour among the ... Eastern Zimbabwe. , Research published today in Science shows how ... prevalence in some groups, which the researchers attribute to people ... partners. , They found HIV prevalence fell most steeply at ...
... the next generation of human therapeutic drugs. , A ... Queensland University of Technology PhD researcher Liam St Pierre ... major trauma. , The genetic code for the toxin, ... Liam St Pierre from QUT's School of Life Sciences ...
... work. Biology researchers at Lewis & Clark College and ... ancient transfer of a toxin between ancestors of two ... remains as how the toxin passed between the two ... journal Bioinformatics, 22(3): 264-268, in an article titled "Lateral ...
Other Biology News:HIV decline in Zimbabwe linked to behavioural change 2Taipan venom no snake oil 2Evolution mystery: Spider venom and bacteria share same toxin 2
Ready-to-use solution....
...
... Polyclonal Antibody Production Conjugated peptides ... ten-week protocol to produce antibodies in 2 ... ml antiserum) ELISA test until the titer ... reaches target titer Protein G purification ...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: